Dr. Benedikt Schoser

PRESS RELEASE Encouraging clinical observations and patient questionnaire results indicate that specific cannabinoid formulations are supportive in the treatment of patients suffering from myotonic dystrophy DENVER–(BUSINESS WIRE)–Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery […]